Atlanta, GA, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Viveon Health Acquisition Corp. (NYSE: VHAQ, VHAQW, VHAQR, VHAQU the "Company") announces that, as previously disclosed in the Current Report on Form 8-K filed on December 26, 2023 with the United States Securities and Exchange Commission, the Company received a letter from the NYSE American LLC ("NYSE American" or the "Exchange") on December 22, 2023, stating that the staff of NYSE Regulation has determined to commence proceedings to delist the Company's Common Stock, Units and Rights (collectively, the "Securities") pursuant to Sections 119(b) and 119(f) of the NYSE American Company Guide because the Company failed to consummate a business combination within 36 months of the effectiveness of its initial public offering registration statement, or such shorter period that the Company specified in its registration statement.
The Company has a right to request that a Committee of the Board of Directors of the Exchange review the delisting determination, provided a written request for such review is requested no later than December 29, 2023. The Company intends to make a request for the review of the delisting determination. At this time, the Securities have not been suspended and will continue to trade.
About Viveon Health Acquisition Corp.
Viveon Health Acquisition Corp. is a blank check company, also commonly referred to as a special purpose acquisition company, or SPAC, formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. It is the Company's intention to pursue prospective targets that are focused on the regenerative medicine, spine and orthopedic industry in the United States and other developed countries.
Forward-Looking Statements
This press release contains certain forward-looking statements that express our opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results and therefore are, or may be deemed to be, "forward-looking statements" within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. These forward-looking statements can generally be identified by the use of forward-looking terminology, including the terms "believes," "estimates," "anticipates," "expects," "seeks," "projects," "intends," "plans," "may," "will" or "should" or, in each case, their negative or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts. They appear in a number of places throughout this press release and include statements regarding our intentions, beliefs or current expectations concerning the Company's performance, business and future events. Such forward looking statements are based on management's expectations, beliefs and forecasts concerning future events impacting the Company. You are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, as well as assumptions, which, if they were to ever materialize or prove incorrect, could cause actual results to differ materially from the from the plans, objectives, expectations, estimates and intentions expressed or implied by such forward-looking statements. The forward-looking statements made in this press release speak only as of the date hereof and we disclaim any obligation, except as required by law, to provide updates, revisions or amendments to any forward-looking statements to reflect changes in our expectations or future events.
Contact: Rom Papadopoulos CFO, Viveon Health Acquisition Corp. 404-861-5393 info@viveonhealth.com |
乔治亚州亚特兰大,2023年12月27日(GLOBE NEWSWIRE)——Viveon Health Acquisition Corp.(纽约证券交易所代码:VHAQ、VHAQW、VHAQR、VHAQU “公司”)宣布,正如先前在2023年12月26日向美国证券交易委员会提交的8-K表最新报告中披露的那样,该公司收到了纽约证券交易所美国有限责任公司(“纽约证券交易所美国公司” 或 “交易所”)于2023年12月22日表示,纽约证券交易所监管机构的工作人员已决定启动程序,将公司的普通股、单位和权利(统称为 “证券”)退市根据《纽约证券交易所美国公司指南》第119(b)和119(f)条,因为该公司未能在其首次公开募股注册声明生效后的36个月内或公司在其注册声明中规定的较短期限内完成业务合并。
公司有权要求联交所董事会委员会审查除名决定,前提是必须在2023年12月29日之前提出书面复审请求。该公司打算要求对除名决定进行审查。目前,证券尚未暂停交易,将继续交易。
关于 Viveon Health Accu
Viveon Health Acquisition Corp. 是一家空白支票公司,通常也被称为特殊目的收购公司(SPAC),其成立的目的是与一家或多家企业进行合并、股票交换、资产收购、股票购买、重组或类似的业务合并。该公司打算在美国和其他发达国家追求以再生医学、脊柱和骨科行业为重点的潜在目标。
前瞻性陈述
本新闻稿包含某些前瞻性陈述,这些陈述表达了我们对未来事件或未来业绩的观点、期望、信念、计划、目标、假设或预测,因此属于《证券法》第27A条和《交易法》第21E条所指的 “前瞻性陈述”。这些前瞻性陈述通常可以通过使用前瞻性术语来识别,包括 “相信”、“估计”、“预期”、“期望”、“寻求”、“项目”、“打算”、“计划”、“可能”、“将” 或 “应该” 等术语,或者在每种情况下都包括其否定或其他变体或类似术语。这些前瞻性陈述包括所有非历史事实的事项。它们出现在本新闻稿的多个地方,包括有关我们对公司业绩、业务和未来活动的意图、信念或当前预期的声明。此类前瞻性陈述基于管理层对影响公司的未来事件的预期、信念和预测。请注意,任何此类前瞻性陈述都不能保证未来的表现,涉及风险和不确定性以及假设,如果这些陈述得以实现或证明不正确,则可能导致实际结果与此类前瞻性陈述所表达或暗示的计划、目标、预期、估计和意图存在重大差异。本新闻稿中的前瞻性陈述仅代表截至本新闻稿发布之日,除非法律要求,否则我们不承担对任何前瞻性陈述提供更新、修订或修正以反映我们预期或未来事件变化的义务。
联系人: 罗姆·帕帕佐普洛斯 Viveon Health 收购公司首席财务官 404-861-5393 info@viveonhealth.com |